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(57) ABSTRACT 
A method of controlling the activity of a biologically active 
compound. The method concerns an oligonucleotide-based 
compound, comprising a hairpin-forming oligonucleotide, an 
effector moiety physically associated with the oligonucle-
otide, where the effector moiety possesses a biological activ-
ity, and a regulating moiety physically associated with the 
oligonucleotide, where the regulating moiety controls the 
biological activity of the effector moiety by interacting with 
the effector moiety. The oligonucleotide can assume a hairpin 
configuration, where the effector and regulating moieties 
interact, or an open configuration, where the effector and 
regulating moieties fail to interact. Depending on the nature 
of the effector and regulating moieties, either configuration 
can result in the expression of the biological activity of the 
effector moiety. 
19 Claims, 6 Drawing Sheets 
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INTELLIGENT NANOMEDICINE 
INTEGRATING DIAGNOSIS AND THERAPY 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims the benefit of U.S. Provisional 
Application No. 60/586,373, filed on Jul. 7, 2004. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
This invention was made with Government Support under 
Grant No. NCC2-1364, awarded by the NASA Ames 
Research Center, and Grant No. NIDCR DE 15018, awarded 
by the National Institute of Health. The Government has 
certain rights in this invention. 
REFERENCE TO A SEQUENCE LISTING 
This application includes a Sequence Listing submitted 
electronically via EFS-Web as a text file named 
"1279424SegList.txt", with a creation date of Jul. 23, 2012 
and a file size of 17.175 kilobytes. The sequence listing is 
incorporated by reference herein in its entirety. 
BACKGROUND 
1. Field of Invention 
This invention relates generally to hairpin-forming oligo-
nucleotides. 
2. Related Art 
With the rapid advances of modem pharmacology, effec-
tive drugs have been discovered for many diseases. However, 
many of these drugs have undesirable side effects due to their 
poor distinction between sick cells and healthy cells. For 
instance, many chemotherapy agents act on cancer cells that 
are actively dividing and replicating. Unfortunately, these 
agents do not discriminate between cancer cells and actively 
dividing normal cells such as blood cells forming bone mar-
row, cells inthe digestivetract, hairfollicles, andreproductive 
cells. As such, the effectiveness of these drugs is limited 
because dosage levels and treatment frequency cannot exceed 
the tolerance levels of normal cells. 
One approach to minimizing the side effects of a drug is to 
target processes predominantly associated with disease 
states. For example, angiogenesis is essential for tumor 
growth but less essential in the normal adult. Therefore, com-
pounds that target angiogenesis may be less toxic. Similarly, 
compounds that limit tumor metastasis may have less side 
effects. Notwithstanding these and other approaches to drug 
development, there is a continuing need to develop drugs 
having reduced side effects. 
SUMMARY 
The present invention concerns an "intelligent' oligo-
nucleotide-based compound that can be activated in sick 
cells, but not healthy cells, due to the integration of diagnostic 
and therapeutic functions into the compound. The diagnostic 
function discriminates between healthy and sick cells and is 
continuously performed by recognizing a biomarker for a 
specific disease. A biomarker is a molecule such as a protein, 
an RNA or DNA, or small organic molecule that is associated 
with a disease state. When the amount of biomarker changes, 
the oligonucleotide-based compound can change its confor-
mation, either activating or deactivating the therapeutic func- 
2 
tions incorporated into the compound. Thus, the oligonucle-
otide-based compound can intelligently adjust its dosage 
according to the amount of biomarker present in a cell. 
In one aspect, the present invention provides a method of 
5 controlling the activity of a biologically active compound. 
The method comprises: a) providing a hairpin-forming oli-
gonucleotide capable of existing in either a hairpin configu-
ration having a single-stranded loop and a double-stranded 
stem, or an open configuration lacking the double-stranded 
l0 
stem; b) physically associating an effector moiety with the 
oligonucleotide, where the effector moiety possesses a bio-
logical activity; c) physically associating a regulating moiety 
with the oligonucleotide, where the regulating moiety con- 
15 trols the biological activity of the effector moiety when the 
regulating and effector moieties interact; and d) changing 
from one configuration to the other. The regulating moiety 
can interact with the effector moiety when the oligonucle-
otide is in the hairpin configuration, while the regulating and 
20 effector moieties fail to interact when the oligonucleotide is in 
the open configuration. 
In another aspect, the present invention provides an oligo-
nucleotide-based compound, comprising: a) a hairpin-form-
ing oligonucleotide; b) an effector moiety physically associ- 
25 ated with the oligonucleotide, where the effector moiety 
possesses a biological activity; and c) a regulating moiety 
physically associated with the oligonucleotide, where the 
regulating moiety controls the biological activity of the effec-
tor moiety by interacting with the effector moiety. The regu- 
30 lating moiety can interact with the effector moiety when the 
oligonucleotide forms a hairpin structure having a single-
stranded loop and a double-stranded stem. The regulating and 
effector moieties fail to interact when the oligonucleotide 
takes an open configuration lacking the double-stranded 
35 stem. 
The oligonucleotide-based compound of the present inven-
tion provides a way to regulate the biological and therapeutic 
activities of a biologically active compound. Depending on 
the nature of the effector and regulating moieties, the biologi- 
40 cal activity of the effector moiety can be expressed in either 
the hairpin or open configurations. 
Other embodiments of the invention include a phannaceu-
tical composition containing an oligonucleotide-based com-
pound of the present invention, and a method of treating 
45 cancer by administering an oligonucleotide-based compound 
to a patient. 
The novel features which are believed to be characteristic 
of the invention, both as to its organization and method of 
operation, together with further objects and advantages will 
50 be better understood from the following description when 
considered in connection with the accompanying figures. It is 
to be expressly understood, however, that each of the figures 
is provided for the purpose of illustration and description only 
and is not intended as a definition of the limits of the present 
55 invention. 
BRIEF DESCRIPTION OF DRAWINGS 
FIG.1 is a schematic drawing of an oligonucleotide-based 
60 compound that is active in the open configuration; 
FIG. 2 is a schematic drawing of an oligonucleotide-based 
compound that is active in the hairpin configuration; 
FIG. 3 is a schematic drawing of an oligonucleotide-based 
compound having cage and plug moieties; 
65 	 FIG. 4 is a schematic drawing of a plurality of oligonucle- 
otide-based compounds associated with a porous drug cap-
sule; 
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FIG. 5 is a schematic drawing of an oligonucleotide-based 	 enzyme, the regulating moiety can control the activity of the 
compound having an antisense sequence in the stem; and 	 enzyme by inhibiting or activating the protein. When the 
	
FIG. 6 provides the structures of two doxorubicin pro- 	 effector moiety comprises a prodrug, the regulating moiety 
drugs. 	 can control the conversion of the prodrug into a therapeuti- 
5 cally active agent. When the effector moiety comprises a 
DETAILED DESCRIPTION 
	
drug, or contains a drug, the regulating moiety can control the 
release of the drug. An antisense molecule can be controlled 
	
In accordance with the present invention, an effector moi- 	 by hybridizing the antisense sequence to a regulating moiety 
	
ety and a regulating moiety are associated with a hairpin- 	 having a sequence complementary to the antisense sequence. 
forming oligonucleotide. As is well known, the hairpin con-  io Other examples will be apparent to those skilled in the art. 
	
figuration of an oligonucleotide comprises a single-stranded 
	
A biomarker is a molecule or substance associated with a 
	
loop region and double-stranded, or duplex, stem region. 	 disease state of a cell or tissue. Examples of biomarkers 
	
Under certain conditions, the duplex stem does not form and 
	
include, but are not limited to, a mutated protein or RNA, an 
	
the oligonucleotide then assumes an open, or non-hairpin, 	 amplified gene, an abnormally modified protein or RNA, an 
configuration. For example, under low salt or high tempera-  15 over-expressed protein or RNA, and high levels of ATP or 
	
ture conditions, the stability of the duplex stem can be 	 Ca 21.  Specific examples of biomarkers useful in cancer 
	
reduced sufficiently such that the oligonucleotide assumes an 	 therapy include mutated ras protein and RNA in cancer cells 
	
open configuration. In certain embodiments of the present 	 of the colon or lung, over-expressed epidermal growth factor 
	
invention, the binding of a biomarker to the loop region of the 	 receptor protein and RNA in prostate, breast and colorectal 
oligonucleotide produces a biomarker-loop combination that 20 cancer cells, and over-expressed vascular endothelial growth 
	
overcomes the duplex stem, resulting in an open configura- 	 factor protein and RNA in breast or pancreatic cancer cells. In 
tion. 	 normal cells, the biomarker is absent or present in limited 
	
In other embodiments, the oligonucleotide forms an open 	 amounts. In such cells, the oligonucleotide-based compound 
	
structure when the single-stranded loop region binds to a 	 is inactive that is, the biological activity of the effector 
molecule provided as a binding partner for the oligonucle-  25 moiety is not expressed. When the biomarker is present in 
	
otide. In certain embodiments, the binding partner is designed 	 unhealthy cells, the oligonucleotide-based compound is 
	
to bind to either the single-stranded loop of the oligonucle- 	 turned on, and the effector moiety expresses its biological 
	
otide or a biomarker, and is designed to bind more strongly to 	 activity. 
	
the biomarker than to the single-stranded loop. In this way, 	 One embodiment of the present invention is shown in FIG. 
when the biomarker is present, the binding partner forms a 30 1. In this embodiment, the oligonucleotide-based compound 
	
biomarker-binding partner hybrid. This removes the binding 	 2 forms a hairpin-structure having a single-stranded loop 4 
	
partner from the oligonucleotide, which can now assume a 	 and double-stranded stem region 6, similar to a molecular 
	
hairpin configuration. The change in structure allows the 	 beacon, with an effector moiety 8 comprising an enzyme and 
	
regulating moiety to interact with the effector moiety. The 	 a regulating moiety 10 comprising an inhibitor of the enzyme. 
binding-partner is provided as a further component of the 35 The inhibitor can occupy or block the active site of the 
oligonucleotide-based compound of the present invention. 	 enzyme, or bind to an allosteric site on the enzyme. The loop 
	
An effector moiety is a small molecule, large molecule, or 	 region 4 of the oligodeoxynucleotide-based compound has a 
	
molecular complex that can carry out or influence a biological 	 sequence complementary to a portion of the nucleotide 
	
process, or, upon interaction with a regulating moiety, can be 	 sequence of a biomarker 12, which in this case is a mutant 
converted to a substance that can carry out or influence a 40 mRNA or an over-expressed gene. When not hybridized to 
	
biological process. Examples of effector moieties include, but 	 the biomarker, the oligonucleotide-based compound is in the 
	
are not limited to: enzymes, which catalyze biological reac- 	 hairpin-configuration and the drug cannot work with its 
	
tions; proteins that bind ligands; drugs and prodrugs, which 
	
inhibitor in close proximity the oligonucleotide-based 
	
alter physiological and cellular processes; anti-sense mol- 	 compound is inactive. When the loop region binds to the 
ecules, which prevent gene expression in cells; and molecular 45 biomarker, the oligonucleotide-based compound opens up 
	
complexes that release stored drugs orprodrugs. Abiological 	 and separates the enzyme and inhibitor, thereby freeing the 
process is a process that can occur in cells or in organisms. 	 enzyme to act the oligonucleotide-based compound is now 
	
The term "biological activity" means the ability of an 	 active. 
	
effector moiety to carry out or influence, or be converted to 	 Another embodiment of the present invention is shown in 
carry out or influence, a biological process. Biological activ-  5o FIG. 2. In this embodiment, the effector moiety 14 is a pro- 
	
ity therefore depends on the nature of the particular effector 	 drug and the regulating moiety 16 is an enzyme that converts 
	
moiety and the biological process carried out or influenced by 	 the prodrug into an active agent. The open and hairpin con- 
	
the particular effector moiety. Preferably, the biological activ- 	 figurations of the oligonucleotide-based compound corre- 
	
ity is a "therapeutic activity", which means a biological activ- 	 spond to the inactive and active states. That is, in the open 
ity directed to the treatment of a disease or condition in a 55 configuration, the enzyme and prodrug are too far apart for 
	
patient. For example, when the disease is cancer, the thera- 	 the enzyme to convert the prodrug into an active agent; thus, 
	
peutic activity can be a biological activity directed to prevent- 	 the oligonucleotide-based compound is inactive. When a 
	
ing the proliferation of cancer cells, or directed to inhibiting 	 hairpin structure is formed, the enzyme acts on the prodrug, 
	
angiogenesis. When the disease state is a vascular condition 	 converting it into an active agent; thus, the oligonucleotide- 
such as myocarditis, which involves the inflammation of the 6o based compound is active. The biomarker 18 is a mutant 
	
myocardium and loss of contractile myocytes dues to apop- 	 mRNA or an over-expressed gene. 
	
tosis and necrosis, the therapeutic activity can be a biological 
	
This embodiment includes a binding partner 20 for the 
activity directed to preventing apoptosis. 	 oligonucleotide. The binding partner binds to the loop of the 
	
The regulating moiety controls the biological activity of 	 oligonucleotide-based compound, thus keeping the com- 
the effector moiety. The way the regulating moiety exerts this 65 pound in the open, inactive configuration. The binding part- 
	
control is varied and depends on the nature of the effector 	 ner is complementary to both the loop sequence and to the 
	
moiety. For example, when the effector moiety comprises an 	 biomarker sequence. Further, the binding partner is designed 
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to have higher affinity for the biomarker than for the loop 
sequence. Thus, in the presence of the biomarker, the binding 
partner binds to the biomarker instead of the loop. This allows 
the oligonucleotide-based compound to assume the hairpin, 
active configuration. Therefore, in the presence of the biom-
arker, the oligonucleotide-based compound is active. 
The binding partner is designed to bind to both the loop 
region of the oligonucleotide and the biomarker. When a 
binding partner is provided and the biomarker is RNA or 
DNA, the loop and the biomarker will generally have similar 
nucleotide sequences. The binding partner is designed to bind 
more strongly to the biomarker than the loop. One way that 
this differential binding can be accomplished is to have the 
binding partner form a longer region of hybridization with the 
biomarker than with the loop. The design of oligonucleotide 
sequences for the binding partner, biomarker and loop can be 
performed by nucleotide sequence programs well known in 
the art. 
In those embodiments where the loop region of a hairpin-
forming oligonucleotide recognizes a biomarker, it will be 
appreciated that the form of the loop region can depend on the 
nature of the biomarker. For example, the loop region can be 
a triple helix-forming oligonucleotide to target DNA, an anti-
sense oligonucleotide to target mRNA, or an aptamer to target 
protein or small molecules such as ATP. Examples and design 
of triple helix-forming oligonucleotides are found in U. S. Pat. 
No. 6,403,302 to Dervan et al., herein incorporated by refer-
ence. Examples and design of antisense oligonucleotides are 
found in U.S. Pat. No. 6,869,795 to Bartelmez et al., herein 
incorporated by reference. Examples and design of aptamer 
sequences are found in U.S. Pat. No. 6,867,289 to Gorenstein 
et al., herein incorporated by reference. 
The oligonucleotide-based compounds of the present 
invention have structures similar to those of molecular bea-
cons. Molecular beacons are based on hairpin-forming oligo-
nucleotides, as described in U.S. Pat. No. 6,037,130 to Tyagi 
et al, incorporated by reference herein. However, in contrast 
to molecular beacons, which contain a pair of fluorophores 
and a quencher, the present invention provides oligonucle-
otide-based compounds containing effector moieties having 
biological activities and regulating moieties controlling those 
biological activities. 
The design of hairpin-forming oligonucleotides is dis-
cussed by Tyagi et al. in U.S. Pat. No. 6,037,130. The oligo-
nucleotide sequences of the hairpin-forming oligonucle-
otides of the present invention can be DNA, RNA, peptide 
nucleic acid (PNA) or combinations thereof. Preferably, the 
oligonucleotides are DNA or RNA, and more preferably, 
RNA. Modified nucleotides may be included, for example 
nitropyrole-based nucleotides or 2'-O-methylribonucle-
otides. Modified linkages also may be included, for example 
phosphorothioates. The hairpin-forming oligonucleotides of 
the present invention can be prepared by any method well 
known in the art. Preferably, the oligonucleotides are pre-
pared by automated synthesis. 
As used herein, the term "oligonucleotide" includes 
derivatives thereof, such as backbone modifications, e.g., 
phosphorothioate derivatives, employed to stabilize the oli-
gonucleotide. All such modifications are contemplated 
equivalents of the hairpin-forming oligonucleotides of the 
invention. The following discussion provides examples of the 
kinds of modifications that may be employed, but those of 
skill in the art will readily recognize others. Non-naturally 
occurring backbones maybe substituted for DNA oligonucle-
otides; such backbones can be more stable than native DNA. 
For example, the oligonucleotides may be provided in stabi-
lized form, e.g. with phosphotriester linkages, or by blocking 
6 
against exonuclease attack with methylphosphonodiester 
linkages, with 3' deoxythymidine, as a phenylisourea deriva-
tive, or by linking other molecules such as aminoacridine or 
polylysine to the 3' end of the oligonucleotide. Base ana- 
5 logues can be substituted for the commonly foundA (adenos-
ine or deoxyadenosine), G (guanosine or deoxyguanosine), C 
(cytidine or deoxycytidine), or T (thymine). Examples 
include, but are not limited to, 7-aza-G and 5-methyl-C. Such 
base analogues are useful for adjusting the melting tempera- 
lo ture of an oligonucleotide, or a segment thereof. Substitution 
of rT (ribothymidine) for U or dU (deoxyuridine) for T are 
also possible. 
In accordance with the present invention, the length of the 
15 loop sequence, the length of the duplex stem, and the relation 
of the two are designed according to the biomarker, any 
binding partner, and the particular regulating and effector 
moieties to be utilized. Lengths of biomarker-recognizing 
sequence and stem hybrid for particular conditions can be 
20 estimated by known means, and experimentally tried and 
adjusted, if necessary. Generally, the loop sequences for use 
in the oligonucleotide-based compounds are in the range of 
16 to 30 nucleotides. Typical stem lengths are in the range of 
3 to 8, more commonly 4 to 7 nucleotides. The strength of the 
25 duplex stem can be adjusted by routine experimentation to 
achieve proper functioning. In addition to length, the strength 
of the duplex stem can be adjusted by altering the G-C content 
and insertion of destabilizing mismatches, as will be appre-
ciated. One strand of the duplex stem is considered to be 
30 complementary to the other strand as long as the strands 
hybridize. A complementary strand can be completely 
complementary, or have mismatches that nonetheless allow a 
duplex to form. A strand having a sequence that is completely 
complementary to the other strand is said to be "perfectly" 
35 complementary. 
A binding partner is a molecule that binds to the loop of the 
hairpin-forming oligonucleotide, resulting in an open struc-
ture. The binding partner can be a protein, oligonucleotide, or 
other small molecule, so long as the binding partner causes 
40 the hairpin-forming oligonucleotide to form an open struc-
ture. Preferably, the binding partner is an oligonucleotide. 
Similar to the hairpin-forming oligonucleotides, the binding 
partner can be DNA, RNA, peptide nucleic acid (PNA) or 
combinations thereof. In preferred embodiments, the binding 
45 partner is DNA or RNA, and more preferably, RNA. 
In designing the hairpin-forming oligonucleotides of the 
present invention, consideration is preferably given to the 
following properties: high resistance to nuclease activity; 
correct intracellular and subcellular delivery; low non-se- 
5o quence-dependent toxicity; high specificity for biomarker; 
appropriate affinity for the biomarker, and good antisense 
effects (for effector moieties containing antisense mol-
ecules). Resistance to nuclease activity and intracellular/sub-
cellular delivery can be attained by appropriate chemical 
55 modification of the oligonucleotides, as is well known in the 
art. For example, chemical modifications for nuclease resis-
tance are described in U.S. Pat. No. 6,867,289 to Gorenstein 
et al., U.S. Pat. No. 6,869,795 to Bartelmez et al., and U.S. 
Pat. No. 6,027,892 to Chang et al., all incorporated by refer- 
60 ence herein. Facilitated delivery can also be attained by use of 
liposomes or other delivery vehicles, as described in U.S. Pat. 
No. 6,803,360 to Chang et al., incorporated by reference 
herein. 
High specificity and appropriate affinity for the biomarker 
65 will depend mainly on the sequence of the loop. As is well 
known, the design of the loop sequence and the stem 
sequence, as well as the design of a binding partner sequence, 
US 8,257,918 B2 
7 
can be performed with the use of software for molecular 
beacon design or other thermodynamic prediction tools. 
An effector moiety or regulating moiety can be connected 
to the hairpin-forming oligonucleotide or included as part of 
the oligonucleotide. For example, an enzyme or prodrug can 5 
be attached to the oligonucleotide by well known chemistries 
such as amine chemistry, thiol chemistry and hydrazine 
chemistry. Alternatively, an anti-sense molecule can be 
included as a portion of one strand of the duplex stem. In 
either case, the moiety is considered to be "physically asso- io 
ciated" with the hairpin-forming oligonucleotide. 
In general, depending on the chemical properties of a par-
ticular effector or regulatory moiety, the attachment of the 
moiety to the hairpin-forming oligonucleotide can be per-
formed during or after synthesis of the oligonucleotide. For 15 
example, in the first case, during the synthesis of the oligo-
nucleotide, themoiety canbe directly incorporated onto the 3' 
of the oligonucleotide by means of a modified solid support 
(CPG) and onto the 5' of the oligonucleotide by means of a 
phosphoramidite reagent. In the second case, during the syn- 20 
thesis of the oligonucleotide, some functional group or 
groups will be added to the oligonucletide. The effector or 
regulating moiety can then be attached to the oligonucleotide 
via the incorporated functional groups. Well-known chemis-
tries that can be used here include amine chemistry, thiol 25 
chemistry and hydrazine chemistry. 
In certain cases, cross-linking reagents can be used to form 
molecular bridges (or linkers) that tie together functional 
groups of two different molecules, e.g., a protein and an 
oligonucleotide. To link two different molecules in a step - 30 
wise manner, hetero-bifunctional cross-linkers can be used 
that eliminate unwanted homopolymer formation. Suitable 
linkers are products of cross-linking reagents that are com-
mercially available (e.g., Pierce Chemical Co.). A wide vari-
ety of cross-linking reagents are available that are capable of 35 
reacting with various functional groups present on the oligo-
nucleotide and effector or regulating moiety. Thus, many 
chemically distinct linkages can be conjugated. Preferably, 
the linker is a product of a cross-linking reagent that com-
prises an active ester, isothiocyano, isocyano, acyl, halo, 40 
maleimido, or active disulfido group. Examples of groups that 
can be used for cross-linking include primary or secondary 
amine groups, hydrazide or hydrazine groups, carboxyl alco-
hol, phosphate, and alkylating groups. 
The use of peptide linkers, such as L-Leu-L-Ala-L-Leu-L- 45 
Ala, is also contemplated. 
As an example of the use of a cross-linking reagent, a 
protein or prodrug can contain a free amino group at one end 
of the molecule. It will react regiospecifically and site spe-
cifically with the heterobifunctional cross-linking reagent 50 
SMCC to form an amide bond. The oligonucleotide, if chemi-
cally modified to contain a free sulfhydryl group, will chemi-
cally combine with SMCC to form a thioether linkage. In this 
example, the linkage formed between the oligonucleotide and 
the effector moiety could be summarized as amide/thioether. 55 
Other linkages between the oligonucleotide and the moiety 
include, but are not restricted to, amide/amide, thioether/ 
amide, disulfide/amide, amide/thioether, and amide/disul-
fide. 
In addition to SMCC, other examples of hetero-bifunc- 60 
tional cross-linkers include, but are not limited to, SMPT, 
SPDP, LC-CPDP, Sulfo-LC-SPDP, Sulfo-SMCC, MBS, 
Sulfo-MBS, SIAB, Sulfo-SIAB, and EDC-Sulfo-NHS. 
The effector and regulating moieties can be connected at 
any location along the hairpin-forming oligonucleotide pro- 65 
vided that the attached moieties do not interfere with the 
hairpin-open configurations, and provided that the regulating  
8 
and effector moieties can interact when the oligonucleotide is 
in the hairpin configuration, and fail to interact in the open 
configuration. Preferably, the effector moiety is attached to 
one end of the oligonucleotide and the regulating moiety to 
the other end. 
Another embodiment of the present invention is shown in 
FIG. 3. The effector moiety in this case comprises a nanofab-
ricated container 22 or "cage". The cage is a compartment 
with a small opening, filled with a drug. The regulating moi-
ety or "plug" 24 is a structure that can block the opening, thus 
preventing the drug from escaping when the cage and the plug 
are brought together. When a biomarker 26 binds to the loop 
of the oligonucleotide-based compound, the compound 
assumes an open configuration, separating the plug from the 
cage. This results in drug 30 being released from the cage. 
In further embodiment is shown in FIG. 4. This embodi-
ment has a plurality of hairpin-forming oligonucleotides 32, 
each with one end immobilized on a porous drug capsule 34, 
which can be constructed using inorganic polymers or natural 
polymers such as DNA. The other end of each oligonucle-
otide has a blocking structure which functions similarly to the 
`plug' in FIG. 3. When a biomarker binds to the loop of one or 
more of the oligonucleotides, the oligonucleotide assumes an 
open configuration, allowing the drug to be released. 
In another embodiment shown in FIG. 5, the effector moi-
ety is an antisense sequence 36 incorporated into a portion of 
the duplex stem of a hairpin-forming oligonucleotide. The 
regulating moiety is a sequence complementary to the anti-
sense sequence. If necessary, the duplex stem can be designed 
to have mismatches between the antisense sequence and the 
regulating complementary sequence such that the antisense 
sequence has greater affinity for the target RNA 38 than for 
theregulating complementary sequence. Whenthe biomarker 
40 is present, the oligonucleotide assumes an open configu-
ration, allowing the antisense sequence to act on the target 
RNA. 
In accordance with the present invention, an oligonucle-
otide-based compound of the present invention can be deliv-
ered to a diseased cell or tissue using various methods for 
delivering nucleic acid molecules. Techniques for in vivo 
delivery of foreign therapeutic nucleic acid molecules are 
known to those skilled in the art. Incorporated herein by 
reference are Zhu, et al., Science 261:209-211(1993), which 
describes the intravenous delivery of cytomegalovirus 
(CMV)-chloramphenicol acetyltransferase (CAT) expression 
plasmid using DOTMA-DOPE complexes; Hyde, et al., 
Nature 362:250-256 (1993), which describes the delivery of 
the cystic fibrosis transmembrane conductance regulator 
(CFTR) gene to epithelia of the airway and to alveoli in the 
lung of mice, using liposomes; and Brigham, et al., Am. J. 
Med. Sci. 298:278-281 (1989), which describes the in vivo 
transfection of lungs of mice with a functioning prokaryotic 
gene encoding the intracellular enzyme chloramphenicol 
acetyltransferase (CAT). 
In preferred embodiments, the oligonucleotide-based com-
pound is delivered as a liposome-nucleic acid complex. Tech-
niques for the formation of cationic lipid-polynucleotide 
complexes are found in Nabel, et al., "Methods for Lipo some-
Mediated Gene Transfer to Tumor Cells in Vivo," Chapter 21, 
Methods in Molecular Medicine, (Ed. P. Robbins, 1997. 
Humana Press Inc., Totowa, N.7.; and Son, et al., "Cationic 
Liposome: Mediated Gene Transfer to Tumor Cells in Vitro 
and In Vivo," Chapter 23, Methods in Molecular Medicine, 
supra, both incorporated by reference herein. Additional non-
limiting examples of preparing liposomes are described in 
US 8,257,918 B2 
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U.S. Pat. Nos. 4,728,578, 4,728,575, 4,737,323, 4,533,254, 
4,162,282, 4,310,505, and 4,921,706, each incorporated 
herein by reference. 
The present invention provides a pharmaceutical compo-
sition comprising a therapeutically effective amount of an 
oligonucleotide-based compound of the present invention, or 
a pharmaceutically acceptable salt thereof. A therapeutically 
effective amount is an amount that results in an improvement 
or a desired change in condition for which the oligonucle-
otide-based compound is administered, when the compound 
is administered once or over a period of time. For example, 
with respect to cancer, the improvement can be reduction in 
the size of a tumor, or a reduction in the symptoms or dis-
comfort associated with the cancer. As is known, the amount 
will vary depending on suchparticulars as the condition being 
treated, the specific oligonucleotide-based compound uti-
lized, the severity of the condition, and the characteristics of 
the patient. 
Pharmaceutically acceptable salts are well known in the art 
and include salts prepared from pharmaceutically acceptable 
non-toxic acids, including inorganic acids and organic acids. 
Suitable non-toxic acids include inorganic and organic acids 
such as acetic, benzenesulfonic, benzoic, camphorsulfonic, 
citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobro-
mic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, 
methanesulfonic, mucic, nitric, pamoic, pantothenic, phos-
phoric, succinic, sulfuric, tartaric acid, p-toluenesulfonic, 
hydrochloric, hydrobromic, phosphoric, sulfuric acids, and 
the like. Salts formed with, for example, a free carboxy group 
of an amino acid residue or a peptide, can be derived from 
inorganic bases including, but not limited to, sodium, potas-
sium, ammonium, calcium or ferric hydroxides, and organic 
bases including, but not limited to, isopropylamine, trimethy-
lamine, histidine, and procaine. 
A pharmaceutical composition of the present invention 
will typically contain a pharmaceutically acceptable carrier. 
Various means of administration are contemplated, such as 
oral, nasal, topical, rectal, inhalation, intramuscular, intrave-
nous, intraperitoneal, and the like. Depending on the intended 
mode of administration, the pharmaceutical compositions 
may be in the form of solid, semi-solid or liquid dosage forms, 
such as, for example, tablets, suppositories, pills, capsules, 
powders, liquids, suspensions, ointments or lotions, prefer-
ably in unit dosage form suitable for single administration of 
a precise dosage. The compositions can include an effective 
amount of the selected oligonucleotide-based compound in 
combination with a pharmaceutically acceptable carrier and, 
in addition, may include other pharmaceutical agents such as 
another therapeutic agent, adjuvants, diluents, buffers, and 
the like. The compounds may thus be administered in dosage 
formulations containing conventional non-toxic pharmaceu-
tically acceptable carriers, adjuvants and vehicles. The 
amount of active compound administered will be dependent 
on the subject being treated, the subject's weight, the manner 
of administration and the judgment of the prescribing physi-
cian. 
The present invention also provides a method of treating 
cancer, comprising administering to an individual a therapeu-
tically effective amount of an oligonucleotide-based com-
pound of the present invention, where the effector moiety 
comprises a molecule having anti-cancer activity and the 
regulating moiety inhibits or activates the anti-cancer activity 
of the effector moiety when the regulating and effector moi-
eties interact. In preferred embodiments, the effector moiety 
comprises an enzyme and the regulating moiety comprises an 
inhibitor of the enzyme. In other embodiments, the effector 
10 
moiety comprises a prodrug and the regulating moiety com-
prises an enzyme that converts the prodrug into a therapeuti-
cally active agent. 
The present invention may be better understood by refer- 
s ring to the accompanying examples, which are intended for 
illustration purposes only and should not in any sense be 
construed as limiting the scope of the invention as defined in 
the claims appended hereto. 
10 	 EXAMPLE 1 
This example describes basic considerations for the design 
of the oligonucleotide-based compounds of the present inven-
15 tion, based on the embodiment shown in FIG. 1. 
Since enzymes are responsible for supporting almost all of 
the chemical reactions involved in every life process, these 
proteins have become one of most important targets in drug 
discovery. There are many clinical drugs based on inhibiting 
20 the activity of enzymes. Well-known known examples of such 
drugs include methotrexate used in cancer chemotherapy to 
semi-selectively inhibit DNA synthesis of malignant cells, 
aspirin used to inhibit the synthesis of prostaglandins which 
are at least partly responsible for the aches and pains of 
25 arthritis, and sulfa drugs used to inhibit the folic acid synthe-
sis that is essential for the metabolism and growth of disease-
causing bacteria. Because inhibitors are such important 
potential drug candidates, many methods have been devel-
oped for their design. Among these methods, the structure- 
30 based methods are most successful (Anderson, A. C., The 
process of structure-based drug design. Chemistry & Biol-
ogy, 2003. 10(9): p. 787-797; Klebe, G., Recent develop-
ments in structure-based drug design, Journal of Molecular 
Medicine-Jmm, 2000. 78(5): p. 269-281; both incorporated 
35 by reference herein). The structures used in the aid of inhibi-
tor design include: 
1. Transition state structure can be used as a guide to design 
new enzyme inhibitors. Based on transition-state theory sug- 
40 gested by Linus Pauling in 1940s, a transition-state interme-
diate exists between the substrates and products in an 
enzyme-catalyzed reaction. Typically, enzymes bind sub-
strates and products with a dissociation constant between 
10-3 to 10' M, while enzymes can bind the transition-state 
45 intermediate with a dissociation constant as low as 10 -24 M. 
Therefore, if only a tiny fraction of that binding energy can be 
captured in a stable compound that mimics the transition-
state intermediate, a potent inhibitor can be found. 
2. Enzyme structure can be used to rationally design inhibi- 
50 tors. There are three primary methods for structure determi-
nation that are useful for inhibitor design: X-ray crystallog-
raphy, NMR, and homology modeling. Structure-based 
design begins with the identification of a potential binding 
site on the enzyme. Ideally, the binding site is a pocket or 
55 protuberance with a variety of potential hydrogen bond 
donors and acceptors, hydrophobic characteristics, and sizes 
of molecular surfaces. Once the structure and target site are 
identified, either experimental or computational methods are 
60 used to design an inhibitor based on the structure of the 
enzyme. The high-throughput screening with combinatorial 
chemistry is a dominant experimental method for inhibitor 
discovery. 
With the above methods, it is possible to design and iden- 
65 tify inhibitors for the cytotoxic enzymes. Therefore, cytotoxic 
enzymes and their inhibitors can be good candidates for the 
effector and regulating moieties shown in FIG. 1. In order to 
5-(Aziridin-1-yl)-4-
hydroxyl-amino-2-
nitro-benzamide 
Unidentified (furan 
epoxide is speculated) 
Isophosphoramide 
mustard 
Cyclophosphamide 	 Phosphoramide mustard 
Fludarabine 	 2-Fluoroadenine 
MeP-dR 	 MeP 
Ganciclovir Ganciclovir- 
triphosphate 
nucleotide 
Etoposide phosphate Etoposide 
Mitomycin C phosphate Mitomycin C 
POMP POM 
N-(4-phosphonooxy)- Doxombicin 
phenylacetyl)doxo- 
rubicin 
Glucuronidated Oxazolidinone 
Nornitrogen mustard 
Glucuronidated 9-Aminocamptothecin 
9-amino-camptothecin 
Glucuronide mustard Mustard 
Methotrexate-amino Methotrexate 
acids 
CMDA Benzoic acid mustard 
DPO Doxombicin 
Me1PO Melphalan 
NHPAP Palytoxin 
N-(phenylacetyl) Doxombicin 
doxorubicin 
N-(phenylacetyl) Melphalan 
melphalan 
Nitroreductase 	 CB 1954 
40 Cytochrome P450 	 4-Ipomeanol 
Cytochrome P450 	 Ifosfamide 
Cytochrome P450 
Purine-nucleoside 
45 phosphorylase 
Purine-nucleoside 
phosphorylase 
Thymidine kinase 
50 Alkaline phosphatase 
Alkaline phosphatase 
Alkaline phosphatase 
Alkaline phosphatase 
55 P-  Glucuronidase 
P- Glucuronidase 
P- Glucuronidase 
Carboxypeptidase 
60 Carboxypeptidase 
Penicillin amidase 
Penicillin amidase 
Penicillin amidase 
Penicillin amidase 
65 Penicillin amidase 
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improve specificity, the inhibitor is preferably noncompeti-
tive, so the inhibition cannot be reversed by substrate. 
EXAMPLE 2 
This example describes basic considerations for the design 
of the oligonucleotide-based compounds of the present inven-
tion, based on the embodiment shown in FIG. 2. 
Prodrugs are pharmacologically inert chemical derivatives 
that can be converted in vivo to the active drug molecules, 
enzymatically or nonenzymatically, to exert a therapeutic 
effect. In the last decade, numerous prodrugs that can be 
enzymatically activated into anti-cancer agents have been 
developed [Rooseboom, M., J. N. M. Commandeur, and N. P. 
E. Vermeulen, Enzyme-catalyzed activation of anticancer 
prodrugs, Pharmacological Reviews, 2004. 56(1): p. 53-102, 
incorporated by reference herein]. A prodrug is an inactive 
reversible chemical derivative of a drug and can be synthe-
sized by covalently linking the drug with a chemical moiety. 
For example, doxorubicin is a DNA-damaging agent and can 
induce cell death through both p53-dependent and -indepen-
dent pathways. Its commonly used therapeutic doses induce 
myelo -suppression and cumulative doses that exceed 550 
Mg/M2 engender a substantial risk of cardiotoxicity. In order 
to reduce the toxicity of doxorubicin, several prodrugs have 
been developed. FIG. 6 shows two of such prodrugs. The one 
shown in FIG. 6(a), HMR 1826, contains glucuronic acid 
conjugated through a linker moiety to the aminoglycoside of 
doxorubicin. This prodrug can be converted to doxorubicin 
by (3-glucuronidase, which is a lysosomal enzyme and is 
commonly found in the necrotic areas of tumors. The prodrug 
shown in FIG. 6(b), N-1-leucyl-doxorubucin (Leu-Dox), 
consists of a leucine amino acid conjugated to the primary 
amine of doxorubicin. The primary mechanism of prodrug 
activation at this site is lysis of the amino-peptidyl bond by 
intracellular lysosomal proteases, resulting in an intracellular 
conversion to free doxorubicin. Both of prodrugs have been 
shown to be more efficient anti-tumor agents than doxorubi-
cin. 
Each of these prodrugs can be attached to a hairpin-form-
ing oligonucleotide as an effector moiety, while their respec-
tive converting enzymes, P-glucuronidase or lysosomal pro-
tease, can be attached as a regulating moiety. When a hairpin 
configuration is formed, the converting enzyme will can act 
on the prodrug, releasing the active agent doxorubicin. 
EXAMPLE 3 
This prospective example is based on the oligonucleotide-
based compound shown in FIG. 1. The effector moiety can be 
a caspase protease (cystein aspartate-specific protease) listed 
in Table 1. Caspases can induce apoptosis in cancer cells. The 
regulatory moiety can be one of the caspase inhibitors listed 
in Table 1. 
TABLE 1 
Caspases Caspases Inhibitor (peptide sequence or name) 
all caspases Ac-Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu- 
Ala-Leu-Leu-AI a-Pro-Val-Ala-Asp-CHO 
(SEQ ID NO: 1) 
Caspases-1 Ac-Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu- 
Ala-Leu-Leu-AI a-Pro-Tyr- Val-Ala-Asp-CHO 
(SEQ ID NO: 2) 
Caspases-2 Ac-Leu-Asp-Glu-Ser-Asp-CHO (SEQ ID NO: 3) 
Caspases-3 Ac-Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu- 
Ala-Leu-Leu-AI a-Pro-Asp-Glu- Val-Asp-C HO 
(SEQ ID NO: 4) 
12 
TABLE 1-continued 
Caspases Caspases Inhibitor (peptide sequence or name) 
Caspases-4 Ac-Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu- 
5 Ala-Leu-Leu-Ala-Pro-Leu-Glu-Val-Asp-CHO 
(SEQ ID NO: 5) 
Caspases-6 Ac-Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu- 
Ala-Leu-Leu-Ala-Pro- Val-Glu-Ile-Asp-CHO 
(SEQ ID NO: 6) 
Caspases-8 Ac-Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu- 
10 Ala-Leu-Leu-Ala-Pro-Ile-Glu-Thr-Asp-CHO 
(SEQ ID NO: 7) 
Caspases-9 Ac-Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu- 
Ala-Leu-Leu-Ala-Pro-Leu-Glu-His-Asp-CHO 
(SEQ ID NO: 8) 
Caspases-13 Ac-Leu-Glu-Glu-Asp-CHO (SEQ ID NO: 9) 
15 	 Caspases-3, 5-[(S)-(+)-2- 
Caspases-7 (Methoxymethyl)pyrrolidino]sulfonylisatin 
The biomarker can be a cancer cell biomarker. When the 
biomarker is absent, the oligonucleotide-based compound 
20 can be in the hairpin configuration, and the caspase can be 
inhibited. When the biomarker is present, the open configu- 
ration is assumed, and the caspase can be active. Active 
caspase can induce apoptosis, which can kill the cancer cell. 
25 	 EXAMPLE 4 
This prospective example is based on the oligonucleotide-
based compound shown in FIG. 2. The effector moiety can be 
a prodrug listed in Table 2. The regulatory moiety can be one 
30 of the activation enzymes listed in Table 2, which is derived 
from Rooseboom, M., J. N. M. Commandeur, and N. P. E. 
Vermeulen, Enzyme-catalyzed activation of anticancer pro-
drugs, Pharmacological Reviews, 2004. 56(1): p. 53-102. 
35 	 TABLE 2 
Activation enzyme 	 Prodrug 	 Drug 
US 8,257,918 B2 
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TABLE 2-continued 
Activation enzyme Prodrug Drug 
P-Lactamase C-DOX Doxombicin 
P-Lactamase PRODOX Doxombicin 
P-Lactamase CM Phenylenediamine 
mustard 
P-Lactamase CCM Phenylenediamine 
mustard 
P-Lactamase Cephalosporin-DACCP DACCP 
P-Lactamase PROTAX Taxol 
P-Lactamase Cephalosporin Mitomycin C 
mitomycin C 
P-Lactamase C-Mel Melphalan 
Cytosine deaminase 5-Fluorocytosine 5-Fluorouracil 
Methionine y4yase Selenomethionine Methylselenol 
Methionine y4yase Trifluoromethionine CSF2 
14 
TABLE 3-continued 
GACAAGACAG GGTGTTGACG ATGCCTTCTA TACATTAGTC 
CGAGAAATTC GAAAACATAA AGAAAAGATG AGCAAAGATG 
5 
GGAAGAAGAA GAAGAAGAAG TCAAGGACAA GGTGTACAGT 
TATGTGA 
G12D Mutant: 	 (SEQ ID NO: 11) 
10 
ATGACTGAGT ATAAACTTGT GGTGGTTGGA GCTGATGGCG 
TAGGCAAGAG CGCCTTGACG ATACAGCTAA TTCAGAATCA 
CTTTGTGGAT GAGTACGACC CTACGATAGA GGACTCCTAC 
15 
AGGAAACAAG TAGTAATTGA TGGAGAAACC TGTCTCTTGG 
In Table 2, MeP is 6-methylpurine; POMP is p-N,N-bis(2-
chloroethyl)aminophenyl phosphate; POM is p-N,N-bis(2-
chloroethyl)aminophenol; DAVLBHYD is 4-desacetylvin-
blastine-3-carboxylic acid hydrazide; DACCP is 20 
4-carboxyphthalato(1,2-cyclohexanediamine) platinum; and 
CSF2 is carbonothionic difluoride. 
The biomarker can be a cancer cell biomarker. When the 
biomarker is absent, the oligonucleotide-based compound 
can be bound to its binding partner, and can be in the open 25 
configuration. When the biomarker is present, the hairpin 
configuration can be assumed, and the activating enzyme can 
act on the prodrug, releasing active drug. 
EXAMPLE 5 	 30 
This prospective example shows various biomarker and 
loop sequences for the an oligonucleotide-based compound 
shown in FIG. 1. The biomarker is based on the ras gene, 
which is the most frequently mutated oncogenes in human 35 
cancers. In inducible K-ras4bG G12D transgenic mice, it has 
been shown that induction of K-ras4b G12D oncogene in the 
basal layer of the epidermis cause formation of malignant 
SCC in the skin and other squamous epithelia. The mRNA of 
K-ras4b G121  can be used as biomarker. 40 
Table 3 lists the cDNA sequence of K-ras and the G12D 
mutant of K-ras. All nucleotide sequences in this and the 
following tables are listed conventionally in the 5'-3' direc-
tion. 
45 
TABLE 3 
Wild: 	 (SEQ ID NO: 10) 
ATGACTGAGT ATAAACTTGT GGTGGTTGGA GCTGGTGGCG 
50 
TAGGCAAGAG CGCCTTGACG ATACAGCTAA TTCAGAATCA 
CTTTGTGGAT GAGTACGACC CTACGATAGA GGACTGCTAC 
AGGAAACAAG TAGTAATTGA TGGAGAAACC TGTCTCTTGG 
55 
ATATTCTCGA CACAGCAGGT CAAGAGGAGT ACAGTGCAAT 
GAGGGACCAG TACATGAGAA CTGGGGAGGG CTTTCTTTGT 
GTATTTGCCA TAAATAATAC TAAATCATTT GAAGATATTC 
ACCATTATAG AGAACAAATT AAAAGAGTAA AGGACTCTGA 
	 60 
AGATGTGCCT ATGGTCCTGG TAGGGAATAA GTGTGATTTG 
CCTTCTAGAA CAGTAGACAC GAAACAGGCT CAGGAGTTAG 
CAAGGAGTTA CGGGATTCCG TTCATTGAGA CCTCAGCAAA 
The possible sequences for the loop 
TABLE 4 
are shown in Table 4. 
No. Loop 
41 CGCCAUCAGCUCCAACCACC (SEQ ID NO: 12) 
42 GCCAUCAGCUCCAACCACCA (SEQ ID NO: 13) 
43 UGCCUACGCCAUCAGCUCCA (SEQ ID NO: 14) 
44 UUGCCUACGCCAUCAGCUCC (SEQ ID NO: 15) 
45 ACGCCAUCAGCUCCAACCAC (SEQ ID NO: 16) 
46 CCAUCAGCUCCAACCACCAC (SEQ ID NO: 17) 
47 UACGCCAUCAGCUCCAACCA (SEQ ID NO: 18) 
48 CUACGCCAUCAGCUCCAACC (SEQ ID NO: 19) 
49 GCCUACGCCAUCAGCUCCAA (SEQ ID NO: 20) 
410 CUUGCCUACGCCAUCAGCUC (SEQ ID NO: 21) 
411 UCUUGCCUACGCCAUCAGCU (SEQ ID NO: 22) 
412 CUCUUGCCUACGCCAUCAGC (SEQ ID NO: 23) 
413 CCUACGCCAUCAGCUCCAAC (SEQ ID NO: 24) 
ATATTCTCGA CACAGCAGGT CAAGAGGAGT ACAGTGCAAT 
GAGGGACCAG TACATGAGAA CTGGGGAGGG CTTTCTTTGT 
GTATTTGCCA TAAATAATAC TAAATCATTT GAAGATATTC 
ACCATTATAG AGAACAAATT AAAAGAGTAA AGGACTCTGA 
AGATGTGCCT ATGGTCCTGG TAGGGAATAA GTGTGATTTG 
CCTTCTAGAA CAGTAGACAC GAAACAGGCT CAGGAGTTAG 
CAAGGAGTTA CGGGATTCCG TTCATTGAGA CCTCAGCAAA 
GACAAGACAG GGTGTTGACG ATGCCTTCTA TACATTAGTC 
CGAGAAATTC GAAAACATAA AGAAAAGATG AGCAAAGATG 
GGAAGAAGAA GAAGAAGAAG TCAAGGACAA GGTGTACAGT 
TATGTGA 
65 	 Stems can be designed for each loop. For example, stems 
(underlined) and possible loop sequences, based on Loop #9, 
are shown in Table 5. 
45 ACGCCAUCAGCUCCAACCAC 
(SEQ ID NO: 37) 
46 CCAUCAGCUCCAACCACCAC 
(SEQ ID NO: 38) 
47 UACGCCAUCAGCUCCAACCA 
(SEQ ID NO: 39) 
48 CUACGCCAUCAGCUCCAACC 
(SEQ ID NO: 40) 
UGGUUGGAGCUGAUGGCG 
(SEQ ID NO: 50) 
UGGUGGUUGGAGCUGAUG 
(SEQ ID NO: 51) 
GGUUGGAGCUGAUGGCGU 
(SEQ ID NO: 52) 
GUUGGAGCUGAUGGCGUA 
(SEQ ID NO: 53) 
US 8,257,918 B2 
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TABLE 5 
(SEQ ID NO: 25) 
UCCGCGCCUACGCCAUCAGCUCCAAGCGGA 
(SEQ ID NO: 26) 5 
ACCGCGCCUACGCCAUCAGCUCCAAGCGGU 
(SEQ ID NO: 27) 
CACCCGCCUACGCCAUCAGCUCCAAGGGUG 
(SEQ ID NO: 28) 10 
CACCGGCCUACGCCAUCAGCUCCAACGGUG 
(SEQ ID NO: 29) 
CCCGAGCCUACGCCAUCAGCUCCAAUCGGG 
(SEQ ID NO: 30) 15 
CCCGUGCCUACGCCAUCAGCUCCAAACGGG 
(SEQ ID NO: 31) 
CCGACGCCUACGCCAUCAGCUCCAAGUCGG 
(SEQ ID NO: 32) 
CCUGCGCCUACGCCAUCAGCUCCAAGCAGG 	 20 
EXAMPLE 6 
TABLE 6 
Binding Partner Oligo Loop sequence 	
35 
41 CGCCAUCAGCUCCAACCACC GUGGUUGGAGCUGAUGGC 
(SEQ ID NO: 33) 	 (SEQ ID NO: 46) 
42 GCCAUCAGCUCCAACCACCA GGUGGUUGGAGCUGAUGG 
(SEQ ID NO: 34) 	 (SEQ ID NO: 47) 
40 
43 UGCCUACGCCAUCAGCUCCA GGAGCUGAUGGCGUAGGC 
(SEQ ID NO: 35) 	 (SEQ ID NO: 48) 
44 UUGCCUACGCCAUCAGCUCC GAGCUGAUGGCGUAGGCA 
(SEQ ID NO: 36) 	 (SEQ ID NO: 49) 
16 
TABLE 6-continued 
Binding Partner Oligo Loop sequence 
49 GCCUACGCCAUCAGCUCCAA UGGAGCUGAUGGCGUAGG 
(SEQ ID NO: 41) 	 (SEQ ID NO: 54) 
410 CUUGCCUACGCCAUCAGCUC AGCUGAUGGCGUAGGCAA 
(SEQ ID NO: 42) 	 (SEQ ID NO: 55) 
411 UCUUGCCUACGCCAUCAGCU GCUGAUGGCGUAGGCAAG 
(SEQ ID NO: 43) 	 (SEQ ID NO: 56) 
412 CUCUUGCCUACGCCAUCAGC 	 CUGAUGGCGUAGGCAAGA 
(SEQ ID NO: 44) 	 (SEQ ID NO: 57) 
413 CCUACGCCAUCAGCUCCAAC 	 UUGGAGCUGAUGGCGUAG. 
(SEQ ID NO: 45) 	 (SEQ ID NO: 58) 
Table 7 shows possible loop and stem (underlined) 
sequences for oligonucleotide-based compounds, based on 
Table 6. 
TABLE 7 
(SEQ ID NO: 59) 
UCCGCUGGAGCUGAUGGCGUAGGGCGGA 
(SEQ ID NO: 60) 
ACCGCUGGAGCUGAUGGCGUAGGGCGGU 
(SEQ ID NO: 61) 
CACCCUGGAGCUGAUGGCGUAGGGGGUG 
(SEQ ID NO: 62) 
CACCGUGGAGCUGAUGGCGUAGGCGGUG 
(SEQ ID NO: 63) 
CCCGAUGGAGCUGAUGGCGUAGGUCGGG 
(SEQ ID NO: 64) 
CCCGUUGGAGCUGAUGGCGUAGGACGGG 
(SEQ ID NO: 65) 
CCGACUGGAGCUGAUGGCGUAGGGUCGG 
(SEQ ID NO: 66) 
CCUGCUGGAGCUGAUGGCGUAGGGUAGG. 
EXAMPLE 7 
25 
This prospective example shows various loop and binding 
partner sequences for an oligonucleotide-based compound 
shown in FIG. 2. As in Example 5, the biomarker is based on 
the ras gene. 
Table 6 shows possible sequences for the binding partner 30 
sequences and the corresponding loop sequences. 
45 	 The following contributions to free energy change can be 
considered in the design of oligonucleotide-based com-
pounds shown in FIG. 1: drug and inhibitor complex break-
age, loop self-structure breakage, biomarker self-structure 
breakage, and loop and biomarker complex formation. 
So The following contributions to free energy change can be 
considered in the design of oligonucleotide-based com-
pounds shown in FIG. 2: loop and binding partner complex 
breakage, diagnosis loop self-structure formation, drug and 
activator complex formation, biomarker self-structure break-
age, and binding partner and biomarker complex formation. 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS: 66 
<210> SEQ ID NO 1 
<211> LENGTH: 19 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
US 8,257,918 B2 
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-continued 
<223> OTHER INFORMATION: Caspases inhibitor 
<400> SEQUENCE: 1 
Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro 
1 	 5 	 10 	 15 
Val Ala Asp 
<210> SEQ ID NO 2 
<211> LENGTH: 20 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Caspases inhibitor 
<400> SEQUENCE: 2 
Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro 
1 	 5 	 10 	 15 
Tyr Val Ala Asp 
20 
<210> SEQ ID NO 3 
<211> LENGTH: 5 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Caspases inhibitor 
<400> SEQUENCE: 3 
Leu Asp Glu Ser Asp 
1 	 5 
<210> SEQ ID NO 4 
<211> LENGTH: 20 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Caspases inhibitor 
<400> SEQUENCE: 4 
Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro 
1 	 5 	 10 	 15 
Asp Glu Val Asp 
20 
<210> SEQ ID NO 5 
<211> LENGTH: 20 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Caspases inhibitor 
<400> SEQUENCE: 5 
Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro 
1 	 5 	 10 	 15 
Leu Glu Val Asp 
20 
<210> SEQ ID NO 6 
<211> LENGTH: 20 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Caspases inhibitor 
<400> SEQUENCE: 6 
US 8,257,918 B2 
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-continued 
Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro 
1 	 5 	 10 	 15 
Val Glu Ile Asp 
20 
<210> SEQ ID NO 7 
<211> LENGTH: 20 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Caspases inhibitor 
<400> SEQUENCE: 7 
Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro 
1 	 5 	 10 	 15 
Ile Glu Thr Asp 
20 
<210> SEQ ID NO 8 
<211> LENGTH: 20 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Caspases inhibitor 
<400> SEQUENCE: 8 
Ala Ala Val Ala Leu Leu Pro Ala Val Leu Leu Ala Leu Leu Ala Pro 
1 	 5 	 10 	 15 
Leu Glu His Asp 
20 
<210> SEQ ID NO 9 
<211> LENGTH: 4 
<212> TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Caspases inhibitor 
<400> SEQUENCE: 9 
Leu Glu Glu Asp 
1 
<210> SEQ ID NO 10 
<211> LENGTH: 	 567 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K- ras4bG12D 
<400> SEQUENCE: 	 10 
atgactgagt ataaacttgt ggtggttgga gctggtggcg taggcaagag cgccttgacg 60 
atacagctaa ttcagaatca ctttgtggat gagtacgacc ctacgataga ggactcctac 120 
aggaaacaag tagtaattga tggagaaacc tgtctcttgg atattctcga cacagcaggt 180 
caagaggagt acagtgcaat gagggaccag tacatgagaa ctggggaggg ctttctttgt 240 
gtatttgcca taaataatac taaatcattt gaagatattc accattatag agaacaaatt 300 
aaaagagtaa aggactctga agatgtgcct atggtcctgg tagggaataa gtgtgatttg 360 
ccttctagaa cagtagacac gaaacaggct caggagttag caaggagtta cgggattccg 420 
ttcattgaga cctcagcaaa gacaagacag ggtgttgacg atgccttcta tacattagtc 480 
cgagaaattc gaaaacataa agaaaagatg agcaaagatg ggaagaagaa gaagaagaag 540 
tcaaggacaa ggtgtacagt tatgtga 567 
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-continued 
<210> SEQ ID NO 11 
<211> LENGTH: 	 567 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K- ras4bG12D 
<400> SEQUENCE: 	 11 
atgactgagt ataaacttgt ggtggttgga gctgatggcg taggcaagag cgccttgacg 60 
atacagctaa ttcagaatca ctttgtggat gagtacgacc ctacgataga ggactcctac 120 
aggaaacaag tagtaattga tggagaaacc tgtctcttgg atattctcga cacagcaggt 180 
caagaggagt acagtgcaat gagggaccag tacatgagaa ctggggaggg ctttctttgt 240 
gtatttgcca taaataatac taaatcattt gaagatattc accattatag agaacaaatt 300 
aaaagagtaa aggactctga agatgtgcct atggtcctgg tagggaataa gtgtgatttg 360 
ccttctagaa cagtagacac gaaacaggct caggagttag caaggagtta cgggattccg 420 
ttcattgaga cctcagcaaa gacaagacag ggtgttgacg atgccttcta tacattagtc 480 
cgagaaattc gaaaacataa agaaaagatg agcaaagatg ggaagaagaa gaagaagaag 540 
tcaaggacaa ggtgtacagt tatgtga 567 
<210> SEQ ID NO 12 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 12 
cgccaucagc uccaaccacc 	 20 
<210> SEQ ID NO 13 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 13 
gccaucagcu ccaaccacca 	 20 
<210> SEQ ID NO 14 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 14 
ugccuacgcc aucagcucca 	 20 
<210> SEQ ID NO 15 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 15 
uugccuacgc caucagcucc 	 20 
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24 
-continued 
<210> SEQ ID NO 16 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 16 
acgccaucag cuccaaccac 	 20 
<210> SEQ ID NO 17 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 17 
ccaucagcuc caaccaccac 	 20 
<210> SEQ ID NO 18 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 18 
uacgccauca gcuccaacca 	 20 
<210> SEQ ID NO 19 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 19 
cuacgccauc agcuccaacc 	 20 
<210> SEQ ID NO 20 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 20 
gccuacgcca ucagcuccaa 	 20 
<210> SEQ ID NO 21 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 21 
cuugccuacg ccaucagcuc 	 20 
<210> SEQ ID NO 22 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 22 
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-continued 
ucuugccuac gccaucagcu 
<210> SEQ ID NO 23 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
20 
<400> SEQUENCE: 23 
cucuugccua cgccaucagc 	 20 
<210> SEQ ID NO 24 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 24 
ccuacgccau cagcuccaac 	 20 
<210> SEQ ID NO 25 
<211> LENGTH: 30 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Sequence of loop SEQ ID NO.: 9 caspeses 
inhibitor plus stems on opposite sides thereof 
<400> SEQUENCE: 25 
uccgcgccua cgccaucagc uccaagcgga 	 30 
<210> SEQ ID NO 26 
<211> LENGTH: 30 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Sequence of loop SEQ ID NO.: 9 caspeses 
inhibitor plus stems on opposite sides thereof 
<400> SEQUENCE: 26 
accgcgccua cgccaucagc uccaagcggu 	 30 
<210> SEQ ID NO 27 
<211> LENGTH: 30 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Sequence of loop SEQ ID NO.: 9 caspeses 
inhibitor plus stems on opposite sides thereof 
<400> SEQUENCE: 27 
cacccgccua cgccaucagc uccaagggug 	 30 
<210> SEQ ID NO 28 
<211> LENGTH: 30 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Sequence of loop SEQ ID NO.: 9 caspeses 
inhibitor plus stems on opposite sides thereof 
<400> SEQUENCE: 28 
caccggccua cgccaucagc uccaacggug 	 30 
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28 
-continued 
<210> SEQ ID NO 29 
<211> LENGTH: 30 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Sequence of loop SEQ ID NO.: 9 caspeses 
inhibitor plus stems on opposite sides thereof 
<400> SEQUENCE: 29 
cccgagccua cgccaucagc uccaaucggg 	 30 
<210> SEQ ID NO 30 
<211> LENGTH: 30 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Sequence of loop SEQ ID NO.: 9 caspeses 
inhibitor plus stems on opposite sides thereof 
<400> SEQUENCE: 30 
cccgugccua cgccaucagc uccaaacggg 	 30 
<210> SEQ ID NO 31 
<211> LENGTH: 30 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Sequence of loop SEQ ID NO.: 9 caspeses 
inhibitor plus stems on opposite sides thereof 
<400> SEQUENCE: 31 
ccgacgccua cgccaucagc uccaagucgg 	 30 
<210> SEQ ID NO 32 
<211> LENGTH: 30 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Sequence of loop SEQ ID NO.: 9 caspeses 
inhibitor plus stems on opposite sides thereof 
<400> SEQUENCE: 32 
ccugcgccua cgccaucagc uccaagcagg 	 30 
<210> SEQ ID NO 33 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 33 
cgccaucagc uccaaccacc 	 20 
<210> SEQ ID NO 34 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 34 
gccaucagcu ccaaccacca 	 20 
<210> SEQ ID NO 35 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
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30 
-continued 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 35 
ugccuacgcc aucagcucca 	 20 
<210> SEQ ID NO 36 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 36 
uugccuacgc caucagcucc 	 20 
<210> SEQ ID NO 37 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 37 
acgccaucag cuccaaccac 	 20 
<210> SEQ ID NO 38 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 38 
ccaucagcuc caaccaccac 	 20 
<210> SEQ ID NO 39 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 39 
uacgccauca gcuccaacca 	 20 
<210> SEQ ID NO 40 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 40 
cuacgccauc agcuccaacc 	 20 
<210> SEQ ID NO 41 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 41 
gccuacgcca ucagcuccaa 	 20 
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32 
-continued 
<210> SEQ ID NO 42 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 42 
cuugccuacg ccaucagcuc 	 20 
<210> SEQ ID NO 43 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 43 
ucuugccuac gccaucagcu 	 20 
<210> SEQ ID NO 44 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 44 
cucuugccua cgccaucagc 	 20 
<210> SEQ ID NO 45 
<211> LENGTH: 20 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 45 
ccuacgccau cagcuccaac 	 20 
<210> SEQ ID NO 46 
<211> LENGTH: 18 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 46 
gugguuggag cugauggc 	 18 
<210> SEQ ID NO 47 
<211> LENGTH: 18 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 47 
ggugguugga gcugaugg 	 18 
<210> SEQ ID NO 48 
<211> LENGTH: 18 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 48 
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ggagcugaug gcguaggc 
<210> SEQ ID NO 49 
<211> LENGTH: 18 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
is 
<400> SEQUENCE: 49 
gagcugaugg cguaggca 	 18 
<210> SEQ ID NO 50 
<211> LENGTH: 18 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 50 
ugguuggagc ugauggcg 	 18 
<210> SEQ ID NO 51 
<211> LENGTH: 18 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 51 
uggugguugg agcugaug 	 18 
<210> SEQ ID NO 52 
<211> LENGTH: 18 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 52 
gguuggagcu gauggcgu 	 18 
<210> SEQ ID NO 53 
<211> LENGTH: 18 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 53 
guuggagcug auggcgua 	 18 
<210> SEQ ID NO 54 
<211> LENGTH: 18 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 54 
uggagcugau ggcguagg 	 18 
<210> SEQ ID NO 55 
<211> LENGTH: 18 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
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-continued 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 55 
agcugauggc guaggcaa 	 18 
<210> SEQ ID NO 56 
<211> LENGTH: 18 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 56 
gcugauggcg uaggcaag 	 18 
<210> SEQ ID NO 57 
<211> LENGTH: 18 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 57 
cugauggcgu aggcaaga 	 18 
<210> SEQ ID NO 58 
<211> LENGTH: 18 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Transgenic mouse expressing K-ras4bG12D 
<400> SEQUENCE: 58 
uuggagcuga uggcguag 	 18 
<210> SEQ ID NO 59 
<211> LENGTH: 28 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Sequence of loop SEQ ID NO.: 58 transgenic 
mouse, eliminating u at the 5' end, plus stems on opposite sides 
thereof 
<400> SEQUENCE: 59 
uccgcuggag cugauggcgu agggcgga 	 28 
<210> SEQ ID NO 60 
<211> LENGTH: 28 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Sequence of loop SEQ ID NO.: 58 transgenic 
mouse, eliminating u at the 5' end, plus stems on opposite sides 
thereof 
<400> SEQUENCE: 60 
accgcuggag cugauggcgu agggcggu 	 28 
<210> SEQ ID NO 61 
<211> LENGTH: 28 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Sequence of loop SEQ ID NO.: 58 transgenic 
mouse, eliminating u at the 5' end, plus stems on opposite sides 
thereof 
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-continued 
<400> SEQUENCE: 61 
cacccuggag cugauggcgu agggggug 	 28 
<210> SEQ ID NO 62 
<211> LENGTH: 28 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Sequence of loop SEQ ID NO.: 58 transgenic 
mouse, eliminating u at the 5' end, plus stems on opposite sides 
thereof 
<400> SEQUENCE: 62 
caccguggag cugauggcgu aggcggug 	 28 
<210> SEQ ID NO 63 
<211> LENGTH: 28 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Sequence of loop SEQ ID NO.: 58 transgenic 
mouse, eliminating u at the 5' end, plus stems on opposite sides 
thereof 
<400> SEQUENCE: 63 
cccgauggag cugauggcgu aggucggg 	 28 
<210> SEQ ID NO 64 
<211> LENGTH: 28 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Sequence of loop SEQ ID NO.: 58 transgenic 
mouse, eliminating u at the 5' end, plus stems on opposite sides 
thereof 
<400> SEQUENCE: 64 
cccguuggag cugauggcgu aggacggg 	 28 
<210> SEQ ID NO 65 
<211> LENGTH: 28 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Sequence of loop SEQ ID NO.: 58 transgenic 
mouse, eliminating u at the 5' end, plus stems on opposite sides 
thereof 
<400> SEQUENCE: 65 
ccgacuggag cugauggcgu agggucgg 	 28 
<210> SEQ ID NO 66 
<211> LENGTH: 28 
<212> TYPE: RNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Sequence of loop SEQ ID NO.: 58 transgenic 
mouse, eliminating u at the 5' end, plus stems on opposite sides 
thereof 
<400> SEQUENCE: 66 
ccugcuggag cugauggcgu agggcagg 	 28 
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What is claimed is: 
1. A method of controlling the activity of a biologically 
active compound, comprising: 
a) providing a hairpin-forming oligonucleotide capable of 
existing in either a hairpin configuration having a single-
stranded loop and a double-stranded stem, or an open 
configuration lacking the double-stranded stem; 
b) physically associating an effector moiety with the oli-
gonucleotide, said effector moiety having a biological 
activity; 
c) physically associating a regulating moiety with the oli-
gonucleotide, said regulating moiety controlling the bio-
logical activity of the effector moiety when the regulat-
ing and effector moieties interact; and 
d) changing from one configuration to the other; 
wherein the regulating moiety interacts with the effector 
moiety when the oligonucleotide is in the hairpin con-
figuration, and the regulating and effector moieties fail 
to interact when the oligonucleotide is in the open con-
figuration, and 
wherein the biological activity comprises sterically block-
ing a target molecule. 
2. The method of claim 1, wherein the biological activity is 
a therapeutic activity. 
3. The method of claim 1, wherein the regulating moiety 
activates the biological activity of the effector moiety. 
4. The method of claim 1, wherein the regulating moiety 
inhibits the biological activity of the effector moiety. 
5. The method of claim 1, wherein binding of the loop to a 
biomarker causes the oligonucleotide to assume its open con-
figuration, whereby the biological activity of the effector 
moiety is expressed. 
6. The method of claim 5, wherein the biomarker is a 
protein or a nucleic acid. 
7. The method of claim 1, further comprising providing a 
binding partner that binds to the loop, thereby causing the 
oligonucleotide to assume its open configuration. 
8. The method of claim 7, wherein the binding partner is a 
protein or a nucleic acid. 
9. The method of claim 7, wherein binding of a biomarker 
to the binding partner causes the oligonucleotide to assume its 
hairpin configuration, whereby the biological activity of the 
effector moiety is expressed. 
10. The method of claim 1, wherein the effector moiety 
comprises an enzyme and the regulating moiety inhibits the 
enzyme when the oligonucleotide is in the hairpin configura-
tion. 
11. The method of claim 1, wherein the effector moiety 
comprises a prodrug and the regulating moiety converts the 
prodrug into a therapeutically active agent when the oligo-
nucleotide is in the hairpin configuration. 
40 
12. The method of claim 1, wherein the effector moiety 
comprises an antisense molecule making up at least a portion 
of one strand of the duplex stem, and the regulating moiety 
comprises at least a portion of the other strand of the duplex 
5 stem and is complementary to the antisense molecule. 
13. The method of claim 1, wherein the effector moiety 
comprises a nanofabricated container enclosing molecules 
having at least one biological activity, and the regulating 
moiety prevents the release of the molecules from the con- 
io tainer when the oligonucleotide is in the hairpin configura-
tion. 
14. A method of controlling the activity of a biologically 
active compound, comprising: 
a) providing a hairpin-forming oligonucleotide capable of 
15 	 existing in either a hairpin configuration having a single- 
stranded loop and a double-stranded stem, or an open 
configuration lacking the double-stranded stem; 
b) attaching an effector moiety to the oligonucleotide, said 
effector moiety having a therapeutic activity; 
20 	 c) attaching a regulating moiety to the oligonucleotide, said 
regulating moiety inhibiting or activating the therapeutic 
activity of the effector moiety when the regulating and 
effector moieties interact; and 
d) changing from one configuration to the other; 
25 wherein the regulating moiety interacts with the effector 
moiety when the oligonucleotide is in the hairpin con-
figuration, and the regulating and effector moieties fail 
to interact when the oligonucleotide is in the open con-
figuration, and 
30 	 wherein the therapeutic activity comprises sterically 
blocking a target molecule. 
15. The method of claim 14, wherein binding of the loop to 
a biomarker causes the oligonucleotide to assume its open 
configuration, whereby the therapeutic activity of the effector 
35 moiety is expressed. 
16. The method of claim 15, wherein the effector moiety is 
an enzyme and the regulating moiety inhibits the enzyme 
when the oligonucleotide is in the hairpin configuration. 
17. The method of claim 14, further comprising providing 
4o a binding partner that binds to the loop, thereby causing the 
oligonucleotide to assume its open configuration. 
18. The method of claim 17, wherein binding of a biomar-
ker to the binding partner causes the oligonucleotide to 
assume its hairpin configuration, whereby the therapeutic 
45 activity of the effector moiety is expressed. 
19. The method of claim 18, wherein the effector moiety 
comprises a prodrug and the regulating moiety converts the 
prodrug into a therapeutically active agent when the oligo-
nucleotide is in the hairpin configuration. 
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